Unilateral Relapsing Primary Angiitis of the CNS
An Entity Suggesting Differences in the Immune Response Between the Cerebral Hemispheres

Mahmoud A. AbdelRazek, MD,* James M. Hillis, MBBS,* Yanjun Guo, MD,* Maria Martínez-Lage, MD, Taha Gholipour, MD, Jacob Sloane, MD, PhD, Tracey Cho, MD, and Marcelo Matiello, MD

Neurol Neuroimmunol Neuromimm 2021;8:e936. doi:10.1212/NXI.0000000000000936

Abstract

Objective
To determine whether studying patients with strictly unilateral relapsing primary angiitis of the CNS (UR-PACNS) can support hemispheric differences in immune response mechanisms, we reviewed characteristics of a group of such patients.

Methods
We surveilled our institution for patients with UR-PACNS, after characterizing one such case. We defined UR-PACNS as PACNS with clinical and radiographic relapses strictly recurring in 1 brain hemisphere, with or without hemiatrophy. PACNS must have been biopsy proven. Three total cases were identified at our institution. A literature search for similar reports yielded 4 additional cases. The combined 7 cases were reviewed for demographic, clinical, imaging, and pathologic trends.

Results
The median age at time of clinical onset among the 7 cases was 26 years (range 10–49 years); 5 were male (71%). All 7 patients presented with seizures. The mean follow-up duration was 7.5 years (4–14.1 years). The annualized relapse rate ranged between 0.2 and 1. UR-PACNS involved the left cerebral hemisphere in 5 of the 7 patients. There was no consistent relationship between the patient’s dominant hand and the diseased side. When performed (5 cases), conventional angiogram was nondiagnostic. CSF examination showed nucleated cells and protein levels in normal range in 3 cases and ranged from 6 to 11 cells/μL and 49 to 110 mg/dL in 4 cases, respectively. All cases were diagnosed with lesional biopsy, showing lymphocytic type of vasculitis of the small- and medium-sized vessels. Patients treated with steroids alone showed progression. Induction therapy with cyclophosphamide or rituximab followed by a steroid sparing agent resulted in the most consistent disease remission.

Conclusions
Combining our 3 cases with others reported in the literature allows better clinical understanding about this rare and extremely puzzling disease entity. We hypothesize that a functional difference in immune responses, caused by such discrepancies as basal levels of cytokines, asymmetric distribution of microglia, and differences in modulation of the systemic immune functions, rather than a structural antigenic difference, between the right and left brain may explain this phenomenon, but this is speculative.

*Co–first authors.

From the Neurology Department (M.A.A.), Mount Auburn Hospital, Harvard Medical School, Cambridge, MA; Neurology Department (J.M.H., M.M.), Massachusetts General Hospital, Harvard Medical School, Boston; Neurology Department (Y.G.), Beijing Tongren Hospital, Capital Medical University, China; Department of Pathology (M.M.-L.), Massachusetts General Hospital, Harvard Medical School, Boston; Neurology Department (T.G.), The George Washington University, DC; Neurology Department (J.S.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and Neurology Department (T.C.), University of Iowa.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Primary angiitis of the CNS (PACNS) was first recognized in 1959 and is characterized by idiopathic inflammation of arteries of the brain, spinal cord, and leptomeninges. The size of the afflicted vessels carries significant diagnostic and prognostic consequences. Disease of predominately small- and medium-sized vessels is often missed by CT angiography, magnetic resonance angiography, and conventional angiography and rather diagnosed with brain biopsy. In such cases, small infarctions are more typical and are associated with a more favorable prognosis overall. Angiitis of large-sized vessels is more likely to have diagnostic angiographic findings and leads to large territorial infarctions and a less favorable prognosis. Our understanding is limited regarding the factors that lead to this difference in the size of the afflicted vessels between different individuals.

Despite the well-known functional differences between the right and left hemispheres of the brain, studies identifying the transcribed RNA in different regions of the brain do not demonstrate a significant difference in gene expression between the 2 hemispheres. Moreover, evidence of asymmetries of total arterial supply between the right and left brain is, similarly, lacking. These data render a readily available explanation for chronic or relapsing asymmetric brain disease difficult to ascertain. In large case series reporting on PACNS, relapsing vasculitis in only 1 hemisphere is not described. Salavarani et al. reported unilateral findings in 8.8% of patients diagnosed by brain biopsy and in 11.5% of patients diagnosed by angiogram, but did not identify whether further relapses continued to focus on the same hemisphere.

Here, we report the diagnostic approach, clinical course, and treatment of 3 cases of unilateral relapsing PACNS (UR-PACNS). In addition, we review the literature and summarize the previously reported cases. We also explore how this disease entity can indicate hemispheric differences in immune response mechanisms.

Methods

The index case (case 1) was identified through its presentation in our institution’s (Massachusetts General Hospital, Boston) weekly neuroimmunology faculty meeting. At that time, other colleagues (M.M., J.M.H. and Y.G.) present at that meeting identified the similar presentation of the patients (cases 2 and 3) who they were following clinically. We queried our Research Patient Data Registry to search for additional patients with UR-PANCS within the last 5 years (January 2015–December 2019). Although 145 patients (53.7% female; average age 54.3, SD 16.9) were seen at Massachusetts General Hospital for suspected cerebral vasculitis, during that time, we did not identify any additional UR-PACNS cases. In our search, UR-PACNS was defined as biopsy-proven PACNS with ≥2 relapses after the initial onset, strictly confined to 1 cerebral hemisphere, with or without relative atrophy of that hemisphere. Relapses were defined as a new clinical neurologic manifestation with brain MRI demonstrating at least 1 new lesion with gadolinium enhancement. If there was no gadolinium enhancement, a relapse could still be recorded if it had been judged by the clinician to be so. We identified 3 such patients, described below in detail. To further characterize this entity, we performed an indexed literature search through PubMed for similar reports using the key words “unilateral, unihemispheric, PACNS, vasculitis, and angiitis” and their synonyms in varying combinations. The references within the identified publications were also reviewed for pertinent studies. This resulted in 4 additional cases. The 7 cases were combined to review demographic, clinical, imaging, and pathologic trends.

Data Availability

Upon appropriate request, the corresponding author can provide deidentified data, e.g., normal serum and CSF tests.

Standard Protocol Approvals, Registrations, and Patient Consents

The authors received written informed consent for research publication from the 3 patients included in the study.

Case Descriptions

Case 1

A 23-year-old right-handed Caucasian woman with a history of migraine headaches and cocaine and alcohol abuse presented in April 2003 with a generalized tonic-clonic seizure. This also coincided with an increased frequency and severity of her headaches. Her migraine history started at age 13 years and was consistent with sporadic hemiplegic migraine, where headaches were associated with transient (~2 hours) weakness of the right arm and leg. Her MRI (4/2003) showed strictly left hemispheric multiple periventricular and deep white matter T2 hyperintense foci, some with faint contrast enhancement (figure 1, A and B) without diffusion-weighted imaging (DWI) changes. CSF analysis was normal without oligoclonal bands. EEG showed intermittent left temporal slowing in the theta and delta range, but no epileptiform activity. She was started on antiepileptic drug (AED) therapy, eventually accumulating 3 AEDs over the course of 4 years for both nonepileptic and 17 epileptic events characterized as...
right arm tonic partial onset seizures with secondary tonic-clonic generalization. Five years after presentation, her neurologic examination was only remarkable for slightly slowed finger-tap speed and alternating movements with the right hand. A formal neuropsychiatric evaluation showed low-normal performance in the executive function and language domains. She was on 1 AED with good seizure control but without a formal diagnosis.

Over the course of the 14 years following her initial presentation, she had 11 more brain MRIs exhibiting progressive unihemispheric atrophy, and a total of 3 clinical relapses associated with new gadolinium-enhancing T2 lesions. All relapses presented clinically with focal or generalized seizure and headache. The first occurred 6 years and 4 months after presentation (figure 1, E and F), and she was started on mycophenolate mofetil for presumed CNS vasculitis without angiographic or pathologic confirmation. The second occurred 7 years and 3 months after presentation; AED regimen was adjusted. Mycophenolate was discontinued 12 years after presentation, which was followed by the third relapse occurring 13 years and 3 months after presentation (figure 1, G and H). Cerebral angiogram was normal, but lesional biopsy showed nongranulomatous, non-necrotizing lymphocytic vasculitis (figure 3). Mycophenolate was restarted, and she received 2 cycles of rituximab 1 g infusions (6 months apart). She has had no further relapses until her last follow-up 14 years after presentation, at which point her neurologic examination was not significantly changed from that documented above, 5 years after presentation. Additional studies included 2 further unremarkable CSF studies (5 years and 13 years 3 months after presentation), unremarkable MRI of the cervical and thoracic spine (3 years from presentation), and serum autoimmune and genetic testing (table 1).

Case 2
A 19-year-old left-handed Caucasian woman presented with a secondarily generalized tonic-clonic seizure that commenced with focal right lower extremity numbness and paresthesia. Brain MRI demonstrated left frontal and parietal multifocal cortical and subcortical T2 hyperintense lesions with contrast enhancement (figure 2, A and B). CSF analysis showed lymphocytic pleocytosis (white blood cell [WBC] 8 cells/μL; 93% lymphocytes, 6% monocytes, and 1% polymorphonuclear cells) and positive CSF oligoclonal bands. She had weakly positive serum antinuclear antibody (1:40). Her laboratory values were otherwise unremarkable (table 1). She was commenced on levetiracetam 500 mg twice daily. One month later, she developed episodes of right upper and lower extremity numbness and paresthesia lasting up to 3 hours. Brain MRI demonstrated interval progression of patchy nodular enhancement within the left cerebellar hemisphere and interval growth of a rounded lesion within the left mesial temporal lobe. She was treated with IV methylprednisolone 1,000 mg daily for 3 days. At follow-up 2 months later, there was interval improvement of symptoms and lesions on brain MRI, although small residual foci of enhancement remained (figure 2, C and D).

Ten months after initial presentation, she developed a prolonged episode of right-sided numbness. Brain MRI showed enhancing lesions in the left temporal, frontal, and parietal lobes. Her dose of levetiracetam was increased to 750 mg twice daily. Twelve months after presentation, she underwent brain biopsy that demonstrated inflammatory and reactive changes, as well as a necrotic focus, consistent with small vessel lymphoplasmacytic vasculitis (figure 3). She was commenced on prednisone 60 mg daily for 6 weeks followed by taper and mycophenolate...
1,000 mg twice daily. Her dose of levetiracetam was also increased to 1,000 mg twice daily postoperatively for worsening right-sided numbness. Four years after initial presentation, she has not had new symptoms or worsening on MRI. She remains on the same therapeutic regimen and continues to have occasional focal seizures.

**Case 3**

A healthy 26-year-old right-handed Chinese man presented to the emergency department in March 2012 with generalized tonic-clonic seizure after an aura of abnormal vision as if witnessing a 3D movie. Brain MRI showed patchy T2 lesions in the right temporal and occipital lobes with multiple nodular and patchy areas of enhancement. CT angiogram of the head was unremarkable apart from showing a common blood supply to both thalami (artery of Percheron). Lumbar puncture opening pressure was 105 mmH2O, with mild pleocytosis (8 WBC/μL) and normal protein (44 mg/dL). Autoimmune encephalitis and ganglioside spectrum antibody panels of CSF were negative. CSF immunoglobulin G index was 0.96 (normal 0.32–0.6). Cryptococcus, cysticercosis antibody, *Mycobacterium tuberculosis* PCR, and bacteria were not detected in CSF. Other normal serum tests are summarized in table 1.

### Table 1 Clinical Features

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age at clinical onset/sex/race</strong></td>
<td>10/M</td>
<td>35/M</td>
<td>49/M/Hispanic</td>
<td>30/M</td>
<td>23/F/Caucasian</td>
<td>19/F/Caucasian</td>
<td>26/M/Chinese</td>
</tr>
<tr>
<td><strong>Handedness</strong></td>
<td>No mention</td>
<td>Right</td>
<td>No mention</td>
<td>Right</td>
<td>Right</td>
<td>Left</td>
<td>Right</td>
</tr>
<tr>
<td><strong>Follow-up duration, y</strong></td>
<td>11.75</td>
<td>10</td>
<td>4</td>
<td>4</td>
<td>14.1</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td><strong>Presenting symptoms</strong></td>
<td>L focal motor seizure, L hemiparesis, and R-sided headache</td>
<td>Generalized seizure, R hemiparesis, and expressive aphasia</td>
<td>R focal seizure, R hemiparesis, and aphasia</td>
<td>R hemiparesis, hemianopia, nonfluent aphasia, and seizures</td>
<td>Generalized tonic-clonic seizure</td>
<td>R focal seizure with secondarily generalized tonic-clonic seizure</td>
<td>Generalized tonic-clonic seizure</td>
</tr>
<tr>
<td><strong>Treatments and responses</strong></td>
<td>Deteriorated on dexamethasone; stable on CYC</td>
<td>Failed steroids, azathioprine, and beta-interferon 1a</td>
<td>Steroids and CYC very successful with near-complete resolution</td>
<td>Pulse steroids, CYC/rituximab induction and MPM maintenance controlled disease for 4 y</td>
<td>Relapse on MPM, followed for 1 y on rituximab without relapse</td>
<td>Steroids, MPM largely successful</td>
<td>Deteriorated on pulse steroids and stable for 1 y on MPM</td>
</tr>
<tr>
<td><strong>Eventual cognitive deficits</strong></td>
<td>No</td>
<td>Yes (aphasia and problem solving)</td>
<td>No</td>
<td>Yes (moderate nonfluent aphasia)</td>
<td>Low-normal executive function and language domains</td>
<td>No</td>
<td>Mild (MMSE 30 and MoCA 26 2 y after onset)</td>
</tr>
<tr>
<td><strong>Eventual motor deficits</strong></td>
<td>L hemiplegia</td>
<td>R hemiparesis</td>
<td>No</td>
<td>Mild R hemiparesis</td>
<td>No</td>
<td>No</td>
<td>R hemiparesis</td>
</tr>
<tr>
<td><strong>Eventual sensory deficits</strong></td>
<td>Hemianopia</td>
<td>No mention</td>
<td>No mention</td>
<td>No mention</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Seizure is the presenting symptom</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes (first seizure during the first hospitalization)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Headache with relapses</strong></td>
<td>Yes</td>
<td>No mention</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>No. of relapses</strong></td>
<td>At least 3</td>
<td>At least 3</td>
<td>At least 4</td>
<td>At least 3</td>
<td>3</td>
<td>At least 4</td>
<td>4</td>
</tr>
<tr>
<td><strong>Annualized relapse rate</strong></td>
<td>0.26</td>
<td>0.3</td>
<td>1</td>
<td>0.75</td>
<td>0.21</td>
<td>1</td>
<td>0.8</td>
</tr>
</tbody>
</table>

Abbreviations: CYC = cyclophosphamide; MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment; MPM = mycophenolate mofetil.
Ten months after presentation, he gradually developed numbness in his left upper limb. Thirteen months after presentation, his left upper and lower limbs were weak. He could not hold light objects. When walking, he felt as if his left lower limb was treading on cotton. He was admitted to a hospital in Beijing, China. Examination showed reduced muscle tone of left upper limb. His left hand showed weakness and incoordination described as thalamic hand. Distal muscle strength of the left upper limb was 4/5, and proximal was 5+/5; the left lower limb was 4/5 proximally and distally. Hoffman sign was present in both hands, and his left toes showed positive Pujupe sign. Brain MRI, 14 months after presentation, showed radiographic progression with patchy T2 lesions in the right thalamus, temporal lobe, frontal lobe, occipital lobe, basal ganglia region, midbrain, and pons. Multiple nodular and patchy enhancement signals were seen in the right cerebral hemisphere. Brain MRI 3 months later (17 months after presentation) showed further progression with all lesions, old and new, remaining strictly confined to the right hemisphere (figure 2, E–G). Lesional biopsy from the superficial right occipital lobe of about 1.5 cm block of subcortical, cortical, and leptomeningeal tissue was performed. Clinical pathologic diagnosis of primary angitis of the CNS was made (figure 3). The patient was commenced on methylprednisolone pulse therapy 1,000 mg/d for 5 days with subsequent oral taper. Despite this, he continued to have gradual clinical and radiographic progression.

Four years and 2 months after initial presentation, his left arm and leg strength had deteriorated further with worsened spasticity. He complained of cognitive deficits, although his Mini-Mental State Examination was 30/30, and Montreal Cognitive Assessment was 26/30. Brain MRI showed further progression with new lesions in the right thalamus, midbrain, upper pons, temporal lobe, occipital lobe, frontal lobe, and basal ganglia region. There was significant atrophy of the right hemisphere and right brainstem (figure 2H). There were new enhancing lesions in the left thalamus. Immunosuppressive therapy with mycophenolate 200 mg twice daily was prescribed accompanied with prednisone 8 mg daily. Ten months later (5 years after presentation), the follow-up brain MRI showed stability with no new lesions, although significant unilateral brain atrophy including the brainstem remained evident.

Results

In addition to the 3 cases we present in this report, there have been 4 prior distinct case reports of biopsy-proven UR-PACNS in patients aged 10, 30, 35, and 49 years at the time of clinical onset (table 1). Although 2 case series from one academic center reported on unilateral intracranial arteriopathy in 93 children, the disease entity described in these pediatric neurology case series differs from UR-PACNS. These reports describe a largely transient monophasic arteriopathy. In the first report, only 5 of 79 children had relapsing arteriopathy, and only 1 of these 5 remained unilateral at follow-up and was thought to be related to neuroborreliosis and not PACNS. In the second report, none of the 14 cases with unilateral arteriopathy had a relapse after a median 8.8-year follow-up and appeared to be monophasic in character.

Demographics, Clinical Course, and Response to Therapy

In the 7 cases that have been reported to date, 3 of whom from this study, the median age at time of clinical onset was 26 years (range 10–49 years); 5 were male (71%); the mean follow-up duration was 7.5 years (4–14.1 years); the mean annualized relapse rate was 0.62 (0.2–1), defined as the average number of clinical relapses with new MRI changes per year. All 7 patients presented with seizures; this is likely related to the small caliber size of the inflicted blood vessels, which tend to
than large-sized vessels. This also explains the presentation of the involvement of small- and medium-sized vessels rather than large-sized vessels. This also explains the presentation of the disease entity is chymal disease on brain MRI leading to a diagnostic brain biopsy. This suggests that the target in this disease entity is a cortical and thus more likely to induce seizure activity. Two of the cases presented with focal unilateral arm and leg convulsions without generalization; in 3 cases, there was associated aphasia; and 4 had hemiparesis not related to Todd paralysis at presentation. Throughout their clinical course, all patients had several clinical and radiographic relapses, 4 patients with headache as a prominent feature, which is the most common symptom in PACNS, occurring in 60% of cases. At the end of the reported follow-up duration, 4 patients had cognitive deficits (language and problem solving), 3 patients had hemiparesis, and 1 had hemiplegia and hemianopia without a deficit in cognition.

The 7 patients varied in response to immunomodulatory therapy as detailed in table 1. Cyclophosphamide and rituximab were successful in suppressing disease relapses whenever used (4 of the 7 cases). Patients who did not receive early induction therapy with these high-potent immunosuppressants showed disease progression. Mycophenolate mofetil was successful as maintenance therapy when it was used after induction therapy in 2 cases. Whenever steroids were used alone, disease was not controlled.

**Neuroimaging**

Conventional cerebral angiogram was performed in 4 of the 7 cases and did not show evidence of vasculitis. Conversely, all cases were diagnosed due to recurring parenchymal disease on brain MRI leading to a diagnostic brain biopsy. This suggests that the target in this disease entity is the involvement of small- and medium-sized vessels rather than large-sized vessels. This also explains the presentation of the 7 cases with seizures, a cortical epiphenomenon more likely to occur with distal vasculitis. Of interest, 2 patients showed asymmetry of the caliber size of the intracranial vessels, one on conventional angiogram and the other on magnetic resonance angiogram. All patients showed recurring gadolinium-enhancing strictly unilateral lesions. In the 3 cases we present, none had DWI restricted diffusion, whereas in the prior 4 cases, there was no specific comment on this. In case 3, only, there was infratentorial involvement, above the level of fiber decussation. This case also showed contralateral thalamic involvement late in the disease, which we believe was related to the common vasculature of both thalami, artery of Percheron, seen on CT angiogram. Table 2 summarizes neuroimaging findings.

In 4 of the 7 cases, there was progressive unilateral volume loss such as that seen in Rasmussen encephalitis, including the midbrain in 1 patient (case 3 of this report). We note that early induction therapy with a strong immunosuppressant was absent in these cases. One case had evidence for subtle volume loss between onset and the first radiographic disease relapse (2 years and 9 months apart), which may indicate subclinical baseline chronic inflammation affecting that single hemisphere with superimposed acute inflammatory episodes causing clinical relapse (case 1 of this report).

**Laboratory Investigations**

Extensive workup for systemic markers of infectious or autoimmune/rheumatologic disease was unremarkable in all patients. The specific workup in each case differed, outlined in
Table 2 Laboratory and imaging features

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CSF analysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive OCB, protein 110 mg/dL, otherwise normal</td>
<td>6 WBC/μL, no OCB, protein 68 mg/dL, and negative VZV DNA</td>
<td>Unremarkable</td>
<td>11 WBC/μL, 87% lymphocytes, protein 50 mg/dL, 2 OCBs, and negative DNA for VZV, HSV, EBV, and CMV</td>
<td>Normal WBC, protein. Immunostain on brain biopsy for VZV is negative.</td>
<td>Positive OCB, 6 WBC/μL, 96% lymphocytes, protein 49 mg/dL, and negative VZV DNA</td>
<td>8 WBC/μL and protein 44 mg/dL</td>
</tr>
<tr>
<td><strong>Conventional angiogram diagnostic of vasculitis (other angiography done)</strong></td>
<td>No (although showed R MCA and its branches of smaller caliber than L)</td>
<td>No (but showed L MCA and R MCA aneurysms)</td>
<td>No mention (MRA showed small caliber of R MCA, ACA, and PCA compared with L)</td>
<td>No</td>
<td>Not performed (although CTA head and neck normal)</td>
<td>Not performed (CTA normal, artery of Percheron seen)</td>
</tr>
<tr>
<td><strong>Parenchymal lesion vascular distribution</strong></td>
<td>R MCA and PCA</td>
<td>L MCA and ACA at least</td>
<td>L MCA</td>
<td>L MCA and PCA</td>
<td>L MCA</td>
<td>L ACA, MCA, and PCA</td>
</tr>
<tr>
<td><strong>Gadolinium enhancement</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Lesion DWI positivity</strong></td>
<td>No mention</td>
<td>No mention</td>
<td>No mention</td>
<td>No mention</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Hemiatrophy on follow-up MRI</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td><strong>Pathologic variant</strong></td>
<td>Lymphocytic</td>
<td>Lymphocytic</td>
<td>Lymphocytic</td>
<td>Lymphocytic</td>
<td>Lymphocytic</td>
<td>Lymphocytic</td>
</tr>
<tr>
<td><strong>Inflamed artery caliber</strong></td>
<td>Small</td>
<td>Small</td>
<td>Small</td>
<td>Small and medium</td>
<td>Small</td>
<td>Small</td>
</tr>
<tr>
<td><strong>Diagnosis made by biopsy or angiogram</strong></td>
<td>Lesional biopsy</td>
<td>Lesional biopsy</td>
<td>Lesional biopsy</td>
<td>Lesional biopsy</td>
<td>Lesional biopsy</td>
<td>Lesional biopsy</td>
</tr>
</tbody>
</table>

Abbreviations: ACA = anterior cerebral artery; CMV = cytomegalovirus; CTA = CT angiography; DWI = diffusion-weighted imaging; EBV = Epstein-Barr virus; HSV = herpes simplex virus; MCA = middle cerebral artery; MRA = magnetic resonance angiography; OCB = oligoclonal band; PCA = posterior cerebral artery; VZV = varicella zoster virus; WBC = white blood cell.

table 2. Noteworthy, CSF examination was overall unremarkable or mildly abnormal. Nucleated cells and protein levels were normal in 3 cases (<6 cells/μL and <46 mg/dL) and ranged from 6 to 11 cells/μL and 49 to 110 mg/dL in the remaining 4 cases, respectively. Oligoclonal bands were mentioned to be positive in 3 cases. Varicella zoster virus (VZV) PCR from CSF was reported to be negative in 3 cases, and immunostaining for VZV on the brain biopsy was negative in a fourth case.

Neuropathology

All 7 cases were diagnosed as PACNS by brain biopsy. Two cases had a nondiagnostic first brain biopsy, one on presentation with a positive biopsy 3 years later, and the second 6 years into the disease with a positive biopsy 2 years after that. The pathologic findings in all 7 cases were consistent with lymphocytic vasculitis of the small- and medium-sized vessels, without evidence of granulomatous or significant vessel wall necrotizing components. In our 3 cases, the most salient finding was transmural and perivascular inflammation, with evidence of ischemic injury from small vessel involvement, most prominent in case 2 (figure 3). No particular finding on biopsy explained the unilateral nature of the vasculitis. Amyloid staining was not performed in any case, likely given the young age (under 50 years) in all patients, the absence of granulomatous changes in all cases, which amyloid beta-related angiitis (ABRA) classically shows, and that ABRA almost exclusively occurs in older patients. VZV immunohistochemical stain was performed in 2 cases (cases 1 and 2) and was negative.

Discussion

The most striking feature of these patients’ presentation was the laterality of their clinical and neuroimaging findings. Although the occurrence of lesions in 1 hemisphere repeatedly may be due to chance, not only did patients have multiple relapses in only 1 hemisphere but also most of the relapses had multiple lesions. For example, in case 3 of this article,
there were at least 10 new enhancing lesions over the course of 4 relapses; thus, the chance of random lateral occurrence would be 0.001 (using the formula $0.5^n$ where $n =$ number of lesions). Similar statistical chance was demonstrated in all 7 cases included here.

In detailed databases of human brain transcriptomes, no difference in the transcribed protein between the 2 hemispheres of the brain was displayed, despite the well-known differences in functional organization between the dominant and nondominant hemispheres. This does not rule out antigenic basis for unilateral vasculitis remains possible. Also, no significant difference in total arterial supply between the 2 hemispheres exists according to the best available evidence. Granted, no immunologic study of the difference between the 2 cerebral hemispheres in arterial wall antigenic structure has been conducted. We did find that 2 of the 7 cases showed hemisphere asymmetry of arterial caliber size, although in 1 case, the diseased hemisphere showed smaller vessels, whereas the opposite was true in the other. Given that no consistent asymmetrical vessel distribution was seen by neuroimaging, it is unlikely that abnormal angiogenesis or a vascular endothelial growth factor–driven process is related to disease mechanisms in these cases. The lymphatic drainage system participates in immune responses and surveillance and could be associated with unilateral inflammation, but there is no current method to measure asymmetry of the lymphatic system. Some researchers advocate for a correlation between handedness and immune response, with reports of an increased tendency toward autoimmune disease (2.5 odds ratio) in left-handed individuals; however, there was no consistent relationship between the patient’s dominant hand and the diseased side of the brain in these 7 cases with UR-PACNS.

Thus, it is more likely that intrinsic hemispheric asymmetries in immune reactivity between the right and left brain, rather than antigenic or structural differences, explain the puzzling unilaterality of disease in these cases. Interhemispheric discrepancies in basal levels of cytokines (e.g., interleukin 1 and interleukin 6), differences in modulation of immune function, and asymmetric distribution of microglia have been described in animal models. In patients with Rasmussen encephalitis, schizophrenia, Creutzfeldt-Jakob disease, and Parkinson disease, interhemispheric discrepancies in genomic and epigenomic states that regulate immune cell development, function, and signaling are implicated in lateralized hemispheric dysregulation. Lateralization of brain functional immune properties may have predisposed to asymmetric inflammatory responses in our patients, but this remains to be determined.

There is the possibility for overlap of UR-PACNS with Rasmussen encephalitis, although the European consensus diagnostic criteria for Rasmussen encephalitis require the exclusion of unihemispheric vasculitis. Indeed, case 1 and case 3 otherwise fulfill the diagnostic criteria. We note that the biopsy results for these cases most prominently suggest perivascular inflammation and do not demonstrate the typical microglial nodules seen with Rasmussen encephalitis. Furthermore, Rasmussen encephalitis commonly presents with seizures in childhood that progress to epilepsy partialis continua. It is possible, however, that Rasmussen encephalitis and UR-PACNS lie on a spectrum of related disorders especially as some Rasmussen biopsies have suggested dual pathology including perivascular lymphocytes. We also note here that anti–myelin oligodendrocyte glycoprotein encephalitis has been reported to mimic CNS vasculitis in histopathologic samples. Unfortunately, serum testing for this was not commercially available during the time frame of follow-up of these patients, and thus, this is a limitation to our report.

In patients with a high diagnostic suspicion of PACNS, we advocate for early brain biopsy. If an initial biopsy is nondiagnostic, and high suspicion remains, we advocate for a second targeted lesional biopsy during disease relapse, ideally including meninges, cortex, and white matter. Two of the 7 cases we reviewed here were diagnosed on the second brain biopsy. Based on current experience from this case series, early induction therapy with cyclophosphamide (15 mg/kg every 2 weeks for 3 doses and then every 3 weeks for 3–6 doses) is advised, followed by maintenance therapy with a steroid sparing agent such as methotrexate (20–25 mg/wk) or mycophenolate (1–2 mg/kg daily). Rituximab (375 mg/m² once a week for 4 doses or 1,000 mg twice, 2 weeks apart; each dose being successful in 1 of the 7 cases) in lieu of cyclophosphamide or as maintenance therapy is also favorable in many cases. In addition, a 3- to 5-day course of IV pulse glucocorticoid therapy during an acute relapse is recommended. Clinical and neuroimaging (brain MRI with contrast) follow-up should be performed once every 1–2 years or more frequently as needed.

**Study Funding**

No targeted funding reported.

**Disclosure**

M.A. AbdelRazek reports no conflict of interest. J.M. Hillis participates in research funded by GE Healthcare and is an investor in Elly Health. Y. Guo, M. Martinez-Lage, and T. Gholipour report no conflict of interest. J. Sloane has served on advisory boards for Biogen, Genentech, Celgene, EMD Serono, Teva, and Genzyme; he has grant funding from Biogen, Genentech, EMD Serono, and the National MS Society. T. Cho reports no conflict of interest. M. Matiello is an advisory board member for Alexion, Genentech, and VielaBio; he is funded by the Clinician-Teacher Development Award by the Mass General Hospital Center for Diversity and Inclusion. Go to Neurology.org/NN for full disclosures.
Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mahmoud A. Abdellazek, MD</td>
<td>Mount Auburn Hospital, Cambridge, MA</td>
<td>Designed and conceptualized the study; analyzed the data; interpreted the data; and drafted the manuscript</td>
</tr>
<tr>
<td>James M. Hillis, MBBS</td>
<td>Massachusetts General Hospital, Boston</td>
<td>Major role in drafting the manuscript for intellectual content and provided patient radiographic data</td>
</tr>
<tr>
<td>Yanjun Guo, MD</td>
<td>Beijing Tongren Hospital, China</td>
<td>Major role in drafting the manuscript for intellectual content and provided patient radiographic data</td>
</tr>
<tr>
<td>Maria Martinez-Lage, MD</td>
<td>Massachusetts General Hospital, Boston</td>
<td>Minor role in drafting the manuscript; revised the manuscript for intellectual content; and reviewed and provided pathology slides and commentary</td>
</tr>
<tr>
<td>Taha Gholipour, MD</td>
<td>The George Washington University, DC</td>
<td>Revisited the manuscript for intellectual content</td>
</tr>
<tr>
<td>Jacob Sloane, MD, PhD</td>
<td>BIDMC, Boston, MA</td>
<td>Revisited the manuscript for intellectual content</td>
</tr>
<tr>
<td>Tracey Cho, MD</td>
<td>University of Iowa</td>
<td>Revisited the manuscript for intellectual content</td>
</tr>
<tr>
<td>Marcelo Mattiello, MD</td>
<td>Massachusetts General Hospital, Boston</td>
<td>Study design; interpreted the data; major role in revising the manuscript for intellectual content; and minor role in drafting the manuscript</td>
</tr>
</tbody>
</table>

References

Unilateral Relapsing Primary Angiitis of the CNS: An Entity Suggesting Differences in the Immune Response Between the Cerebral Hemispheres
Mahmoud A. AbdelRazek, James M. Hillis, Yanjun Guo, et al.
*Neurol Neuroimmunol Neuroinflamm* 2021;8;
DOI 10.1212/NXI.0000000000000936

This information is current as of January 5, 2021

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/8/2/e936.full.html">http://nn.neurology.org/content/8/2/e936.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 29 articles, 4 of which you can access for free at: <a href="http://nn.neurology.org/content/8/2/e936.full.html##ref-list-1">http://nn.neurology.org/content/8/2/e936.full.html##ref-list-1</a></td>
</tr>
</tbody>
</table>
| Subspecialty Collections | This article, along with others on similar topics, appears in the following collection(s):  
  | **All Immunology** [http://nn.neurology.org/cgi/collection/all_immunology](http://nn.neurology.org/cgi/collection/all_immunology)  
  | **Autoimmune diseases** [http://nn.neurology.org/cgi/collection/autoimmune_diseases](http://nn.neurology.org/cgi/collection/autoimmune_diseases)  
  | **Infarction** [http://nn.neurology.org/cgi/collection/infarction](http://nn.neurology.org/cgi/collection/infarction)  
  | **Vasculitis** [http://nn.neurology.org/cgi/collection/vasculitis](http://nn.neurology.org/cgi/collection/vasculitis) |
| Permissions & Licensing | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: [http://nn.neurology.org/misc/about.xhtml#permissions](http://nn.neurology.org/misc/about.xhtml#permissions) |
| Reprints | Information about ordering reprints can be found online: [http://nn.neurology.org/misc/addir.xhtml#reprintsus](http://nn.neurology.org/misc/addir.xhtml#reprintsus) |

*Neurol Neuroimmunol Neuroinflamm* is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.